Cevostamab (Anti-FCRL5 no CD3) Biosimilar Antibody (HDBS0082)
The Cevostamab biosimilar Anti-FCRL5 (no CD3) Antibody is a novel biopharmaceutical designed for targeted therapy in the treatment of certain cancers. This antibody specifically targets the FCRL5 receptor, which is highly expressed on B-cell malignancies such as leukemia and lymphoma. By blocking the FCRL5 receptor, this antibody can effectively inhibit the growth and spread of cancer cells, making it a promising option for patients with these types of cancers.This biosimilar antibody is produced using advanced recombinant technology, ensuring high purity and potency for use in clinical settings. It has been extensively tested in preclinical studies and has shown promising results in inhibiting tumor growth without affecting normal healthy cells.
Additionally, its unique design without CD3 targeting minimizes the risk of cytokine release syndrome, a common side effect of some immunotherapies.Overall, the Cevostamab biosimilar Anti-FCRL5 (no CD3) Antibody represents a cutting-edge approach to cancer treatment, offering a targeted and effective therapy option for patients with B-cell malignancies. Its potential to improve outcomes and quality of life for cancer patients makes it a valuable addition to the treatment arsenal in the fight against cancer.
Product Name:
Cevostamab (Anti-FCRL5 no CD3) Biosimilar Antibody
Size:
100 ug
Product SKU:
HDBS0082
Target:
FCRL5
Host Species:
Humanized
Reactivity:
Human
Recommended Dilution:
ELISA 1:5000-10000; Flow Cyt 1:100
Antibody Type:
Monoclonal
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
BFCR-4350-A, BFCR-4350A, RG-6160, RO-7187797
Description:
Anti-FCRL5(cevostamab biosimilar without anti-CD3 portion) mAb
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
